Zacks Investment Research upgraded shares of SenesTech (NASDAQ:SNES) from a sell rating to a hold rating in a research note issued to investors on Tuesday.
According to Zacks, “SenesTech, Inc. developed technology for managing animal pest populations through fertility control as opposed to a lethal approach. The Company’s fertility control product candidate, ContraPest(R), will be marketed for use initially in controlling rat infestations. SenesTech, Inc. is based in Flagstaff, Arizona. “
SNES stock opened at $0.79 on Tuesday. The company has a quick ratio of 4.07, a current ratio of 5.05 and a debt-to-equity ratio of 0.05. The firm has a market cap of $18.51 million, a price-to-earnings ratio of -0.71 and a beta of 0.29. SenesTech has a 52-week low of $0.30 and a 52-week high of $3.87.
SenesTech (NASDAQ:SNES) last posted its earnings results on Monday, August 13th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.12). The business had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.40 million. SenesTech had a negative return on equity of 214.75% and a negative net margin of 13,362.22%. As a group, equities research analysts anticipate that SenesTech will post -0.61 earnings per share for the current fiscal year.
A hedge fund recently bought a new stake in SenesTech stock. Bank of Montreal Can bought a new position in shares of SenesTech Inc (NASDAQ:SNES) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 80,000 shares of the company’s stock, valued at approximately $131,000. Bank of Montreal Can owned about 0.48% of SenesTech as of its most recent SEC filing. 8.03% of the stock is owned by institutional investors.
SenesTech, Inc develops a technology for managing animal pest populations through fertility control. The company focuses on commercializing ContraPest, a fertility control product for use in controlling rat populations. It is also developing a pipeline of fertility control and animal health products, including feral animal fertility control, non-surgical spay and neutering, boar taint, and animal cancer treatment.
Read More: How to Invest in the Dividend Aristocrat Index
Get a free copy of the Zacks research report on SenesTech (SNES)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SenesTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SenesTech and related companies with MarketBeat.com's FREE daily email newsletter.